English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

In general head and neck cancer may be treated with single modality of treatment for early stage disease but may require multimodality treatment protocol for advanced disease. concurrent chemoradiation is the current standard protocol for patients with locally advanced squamous cell carcinoma of head neck. Carcinoma of head and neck is common clinical entity approximately 3.2% of the total newcancer cases. In Bangladesh, according to cancer Registry Report NICRH (2008-2010), approximately 2901(10.6%) patients ire registered with head and neck cancer. Study Design and Objective: This prospective observational study is to compare the treatment response and acute toxicities with the treatment of low dose weekly Paclitaxel with radiation versus weekly Cisplatin with radiation therapy for histologically proven advanced squamous cell carcinoma of head neck. Methods: All the patients were divided in two groups. Arm-A 30 number patients received injection Paclitaxel 40mg/m2, i/v 1 hr. infusion weekly for 6 weeks and ArmB 30 number patients received injection Cisplatin 30mg/m2, i/v 2 hrs infusion weekly for 6 weeks. All patients received 66 Gray(Gy) radiation at the rate of 2Gy/day 5# in a week for 6.5 weeks. Results: In this study ninety percent (90%) patients were smoker. The most common presenting features were cervical lymphadenopathy (Arm A 100% vs. Arm B 100%), pain (Arm A 73.33% vs. Arm B 66.67%), sore throat (Arm A 36.67% vs. Arm B 36.66%), hoarseness of voice (Arm A 36.67% vs. Arm B 36.66%) etc. Complete response of patients treated with concurrent chemoradiation with inj. Paclitaxel was 63.33% in comparison to 53.33% complete response achieved in patients treated with concurrent chemoradiation with inj. Cisplatin. This difference was statistically not much more significant. Common toxicities realated to treatment were mucosities, skin reaction, vomiting, nausea, weight loss, anaemia, leucopcnia, thrombocytopenia and diarrhoea. The toxicities in Arm-A were more than that of Arm-B, but were manageable. Conclusion: In this study the clinical response and taxicities produced by weekly low dose paclitaxel with radiation in locally advanced squamous cell carcinoma of head and neck cancer were comparable to those of weekly Cisplatin schedule with radiation showed no additional efficacy. So, concurrent chemoradiotherapy with weekly Paclitaxel is suitable when Cisplatin is contraindicated for the patients with renal impairment.

journal of medical science and clinical research

Low dose weekly paclitaxel with radiation is an acceptable alternative for weekly cisplatin with radiation in the treatment of advanced head neck carcinoma: An observational study